21:00 , Apr 12, 2019 |  BC Extra  |  Company News

J&J's Balversa gets accelerated approval for bladder cancer

FDA granted Janssen's Balversa erdafitinib accelerated approval to treat bladder cancer, making it the first FGFR kinase inhibitor to gain U.S. approval. Balversa is indicated to treat adults with locally advanced or metastatic urothelial carcinoma...
23:51 , Feb 21, 2019 |  BC Week In Review  |  Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
21:30 , Feb 19, 2019 |  BC Extra  |  Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
20:27 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

Basilea Pharmaceutica Ltd. (SIX:SLN) reported interim data from the pivotal Phase II ARQ 087-301 trial to treat intrahepatic cholangiocarcinoma showing derazantinib led to an objective response rate (ORR) of 21% and a disease control rate...
18:33 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Principia seeks IPO ahead of Phase III trials for Btk program

Principia Biopharma Inc. (South San Francisco, Calif.) proposed late Aug. 17 to raise $86.3 million in an IPO on NASDAQ and revealed that it raised $49.7 million in a series C round this month. Underwriters...
20:21 , Aug 20, 2018 |  BC Extra  |  Financial News

With Btk program bound for Phase III, Principia seeks IPO

Principia Biopharma Inc. (South San Francisco, Calif.) proposed late Friday to raise $86.3 million in an IPO on NASDAQ and revealed that it raised $49.7 million in a series C round this month. Underwriters are...